MAP Kinase Kinase 1, antagonists & inhibitors

Name
MAP Kinase Kinase 1, antagonists & inhibitors
Accession Number
DBCAT001678
Description

Not Available

Drugs
DrugDrug Description
CobimetinibAn antineoplastic agent and selective inhibitor of the mitogen-activated extracellular kinase (MEK) pathway used to treat unresectable or metastatic melanoma.
TrametinibA kinase inhibitor used alone or in combination with dabrafenib to treat patients with cancers with specific BRAF mutations, such as melanoma and non-small cell lung cancer.
BinimetinibA medication used to treat metastatic melanoma with specific mutations.
Drugs & Drug Targets
DrugTargetType
CobimetinibDual specificity mitogen-activated protein kinase kinase 1target
CobimetinibCytochrome P450 3A4enzyme
CobimetinibSolute carrier organic anion transporter family member 1B1transporter
CobimetinibSolute carrier organic anion transporter family member 1B3transporter
CobimetinibATP-binding cassette sub-family G member 2transporter
CobimetinibP-glycoprotein 1transporter
CobimetinibUDP-glucuronosyltransferase 2B7enzyme
CobimetinibCytochrome P450 2D6enzyme
CobimetinibCytochrome P450 3A5enzyme
CobimetinibAlpha-1-acid glycoprotein 1carrier
TrametinibCytochrome P450 2C8enzyme
TrametinibCytochrome P450 3A4enzyme
TrametinibDual specificity mitogen-activated protein kinase kinase 1target
TrametinibDual specificity mitogen-activated protein kinase kinase 2target
BinimetinibUDP-glucuronosyltransferase 1-1enzyme
BinimetinibCytochrome P450 1A2enzyme
BinimetinibCytochrome P450 2C19enzyme
BinimetinibDual specificity mitogen-activated protein kinase kinase 2target
BinimetinibSerum albumincarrier
BinimetinibDual specificity mitogen-activated protein kinase kinase 1target
BinimetinibATP-binding cassette sub-family G member 2transporter
BinimetinibP-glycoprotein 1transporter